Journal
BMC COMPLEMENTARY MEDICINE AND THERAPIES
Volume 20, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12906-020-2857-1
Keywords
Curcumin; Demethoxycurcumin; Bisdemethoxycurcumin; Apoptosis; Osteosarcoma
Categories
Funding
- National Science Council, Taiwan [MOST 107-2320-B-007-001, MOST 108-2320-B-007 -006 -MY3]
Ask authors/readers for more resources
Background: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents and has also been associated with a high degree of malignancy and enhanced metastatic capacity. Curcumin (CUR) is well known for its anti-osteosarcoma activity. However, both demethoxycurcumin (DMC), and bisdemethoxycurcumin (BDMC) are natural curcumin analogues/congeners from turmeric whose role in osteosarcoma development remains unknown. Methods: To evaluate the growth inhibitory effects of CUR, DMC and BDMC on osteosarcoma (HOS and U2OS), breast (MDA-MB-231), and melanoma (A2058) cancer cells, we employed the MTT assay, annexin V-FITC /7-AAD staining, and clonogenic assay. Results: CUR,DMC, and BDMC all decreased the viability of HOS, U2OS, MDA-MB-231, and A2058 cancer cells. Additionally, CUR,DMC, and BDMC induced the apoptosis of HOS cells through activation of Smad 2/3 or repression of Akt signaling pathway. Furthermore, the combination of CUR,DMC, and BDMC synergistically reduced cell viability, colony formation and increased apoptosis than either two or a single agent in HOS cells. Conclusions: The combination of these three compounds could be used as a novel target for the treatment of osteosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available